Zura Bio Ltd

ZURA

Held by 3 specialist biotech funds

High Convergence

3 funds opened new positions. Next phase2 readout (Tibulizumab Dose A): Nov 2026. Short interest: 6.9% of float.

BiotechnologyCEO: Sandeep C. KulkarniIPO: 2023Website ↗

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

Zura Bio Ltd

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links

Related Research